|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.
Medtronic (MDT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Boston Scientific Corp NYSE:BSX